Nasdaq · CIK 0000730272 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
REPLIGEN CORP
RGEN chart by TradingView
PRICE HISTORY
LIVE · NASDAQRGEN chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.7B
- EBITDA
- $0.1B
- FREE CASH FLOW
- $0.1B
- EPS
- $864.45
- GROSS MARGIN
- 52.32%
- ROIC
- 2.35%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
186.0x
+24%0.1x223.8x
⤢
P / SALES (TTM)
9.8x
-5%0.0x28.0x
⤢
P / BOOK
3.7x
-41%0.0x7.6x
⤢
EV / EBITDA (TTM)
53.4x
+59.9x-6.5x53.4x
⤢
EV / REVENUE (TTM)
9.8x
+10.1x-0.4x9.8x
⤢
FCF YIELD (TTM)
1.45%
+1.0pp-0.06%1856.99%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.2B
+727%⤢
EBITDA (DERIVED)
$0.0B
+358%⤢
NET INCOME
$0.0B
+334%⤢
EPS (DILUTED)
$0.09
+163%⤢
REVENUE GROWTH YOY
11.93%
-12.6pp-29.66%89.47%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
13.44%
+26.6pp-13.14%33.77%
⤢
RETURN ON CAPITAL
2.02%
+3.5pp-1.47%2.48%
⤢
RETURN ON EQUITY (TTM)
1.97%
-2.2pp-1.29%9.73%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN53.91%
OPERATING MARGIN6.85%
NET MARGIN2.45%
FCF MARGIN13.44%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.0B
+$0.0B⤢
STOCK-BASED COMP
$0.0B
+525%⤢
CAPITAL EXPENDITURE
$0.0B
+159%⤢
SHARES OUTSTANDING
0.06B
+65%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.6B
+285%⤢
TOTAL DEBT
$0.6B
+5%⤢
DEBT / EBITDA (TTM)
3.8x
-75%3.8x15.2x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 119.99%INSIDERS 5.24%OTHER / RETAIL 0.00%635 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 10.62% | 6.0M | $982.3M | -9.5% |
| Price (T.Rowe) Associates Inc | 8.64% | 4.9M | $799.5M | +6.1% |
| FMR, LLC | 5.12% | 2.9M | $473.1M | +0.7% |
| United Capital Financial Advisors, LLC | 4.92% | 2.8M | $454.7M | +0.1% |
| Vanguard Capital Management LLC | 4.25% | 2.4M | $392.8M | NEW |
| Vanguard Portfolio Management LLC | 4.08% | 2.3M | $377.8M | NEW |
| State Street Corporation | 3.15% | 1.8M | $291.3M | +3.4% |
| Massachusetts Financial Services Co. | 2.87% | 1.6M | $265.0M | +15.7% |
| Wasatch Advisors LP | 2.82% | 1.6M | $260.6M | +27.9% |
| Bank Of New York Mellon Corporation | 2.70% | 1.5M | $249.6M | -0.6% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.